Document:

Exhibit 10.1

 

Execution Version

 

AMENDED AND RESTATED

COOPERATION AGREEMENT

 

This Amended and Restated Cooperation Agreement
(this “Agreement”), dated as of July 11, 2022, is entered into by and among Dave & Buster’s Entertainment, Inc.,
a Delaware corporation (the “Company”), James Chambers, an individual, and Hill Path Capital LP, a Delaware limited
partnership (“Hill Path” and together with James Chambers, the “Hill Path Parties”). This Agreement
amends and restates in full the Cooperation Agreement by and among the Company, James Chambers, and Hill Path, dated as of December 18,
2020.

 

In consideration
of and reliance upon the mutual covenants and agreements contained herein, and for other good and valuable consideration, the receipt
and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:

 

1.            Defined
Terms. Capitalized terms used in this Agreement and not otherwise defined have the following meanings:

 

(a)            “Affiliate”
shall have the meaning set forth in Rule 12b-2 promulgated under the Exchange Act and shall include Persons who become Affiliates
of any Person subsequent to the date of this Agreement;

 

(b)            “beneficially
own”, “beneficially owned” and “beneficial ownership” shall have the meaning set forth
in Rules 13d-3 and 13d-5(b)(l) promulgated under the Exchange Act;

 

(c)            “business
day” shall mean any day other than a Saturday, Sunday or a day on which the Federal Reserve Bank of New York is closed;

 

(d)            “Company
Policies” shall mean the confidentiality, conflicts of interest, related party transactions, codes of conduct, trading and disclosure,
director resignation and other guidelines and policies of the Company;

 

 (e)           “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended;

 

(f)            “Expiration
Date” means the date that is ten (10) days after such time as Hill Path Designee is no longer a member of the Board;

 

(g)            “Extraordinary
Transaction” means any tender offer, takeover, merger, acquisition, business combination, recapitalization, restructuring, issuance
of common stock or any other strategic or change of control transaction involving the Company or the assets or business of the Company,
its subsidiaries and joint ventures, taken as a whole, in each case where the aggregate consideration is more than $130 million in whatever
form, cash or stock;

 

(h)            “Hill
Path Designee” means an individual designated by Hill Path to the Board in accordance with this Agreement, and who as of the
date hereof is James Chambers.

 

     

     

    

 

(i)            “Independent”
means that a Person shall be an independent director of the Company under the Company’s independence guidelines, applicable law
and the rules and regulations of the SEC and the Nasdaq Stock Market;

 

(j)            “Person”
shall be interpreted broadly to include, among others, any individual, general or limited partnership, corporation, limited liability
or unlimited liability company, joint venture, estate, trust, group, association or other entity of any kind or structure;

 

(k)            “Synthetic
Position” shall mean any option, warrant, convertible security, stock appreciation right, or other security, contract right
or derivative position or similar right (including any “swap” transaction with respect to any security, other than a broad
based market basket or index) (each of the foregoing, a “Derivative”), whether or not presently exercisable, that has
an exercise or conversion privilege or a settlement payment or mechanism at a price related to the value of any equity securities of the
Company or a value determined in whole or in part with reference to, or derived in whole or in part from, the value of any equity securities
of the Company and that increases in value as the market price or value of any such securities increases or that provides an opportunity,
directly or indirectly, to profit or share in any profit derived from any increase in the value of any such securities, in each case regardless
of whether (i) it conveys any voting rights in such securities to any Person, (ii) it is required to be or capable of being
settled, in whole or in part, in cash or in equity securities of the Company or otherwise or (iii) any Person (including the holder
of such Synthetic Position) may have entered into other transactions that hedge its economic effect.

 

(l)            “Third
Party” means any Person that is not a party to this Agreement or an Affiliate thereof, a member of the Board, a director or
officer of the Company, or legal counsel to any party to this Agreement; and

 

(m)            “Voting
Securities” shall mean the shares of common stock of the Company and any other securities of the Company entitled to vote in
the election of directors, or securities convertible into, or exercisable or exchangeable for, such shares or other securities, whether
or not subject to the passage of time or other contingencies.

 

2.            Voting
of Hill Path’s Shares. During the Restricted Period (as defined below), in the event Hill Path and its Affiliates obtain
(as a result of buybacks or repurchases by or on behalf of the Company, purchases by Hill Path and/or its Affiliates, or otherwise) beneficial
ownership in excess of 15% of the outstanding Voting Securities (the “Excess Voting Rights”), and for so long as Hill
Path and its Affiliates continues to (i) have the right to exercise such Excess Voting Rights and (ii) beneficially own more
than 15% of the outstanding Voting Securities, Hill Path and its Affiliates shall (A) on each and every matter that is submitted
to the stockholders of the Company for their vote and with respect to which the Excess Voting Rights may be voted by Hill Path or any
of its Affiliates, exercise such Excess Voting Rights in the same proportion in which all other Voting Securities voted on such matter
are voted (without taking into consideration, in determining such proportions, (x) any Voting Securities that are not voted or with
respect to which a “nonvote” or abstention is exercised or registered and (y) any Voting Securities that are voted by
Hill Path or any of its Affiliates on such matter), and (B) take reasonable steps to cooperate with the Company in order to exercise
such Excess Voting Rights in the manner contemplated by this Section 2.

 

    2

     

    

 

3.            Company
Policies. The parties hereto acknowledge that the Hill Path Designee will, in accordance with this Agreement, serve as a member
of the Board and will be governed by the same protections and obligations as a member of the Board (including as set forth in the Company
Policies), and shall have the same rights and benefits, including with respect to insurance, indemnification, compensation and fees, as
are applicable to all independent directors of the Company. Hill Path agrees to comply with all Company Policies applicable to the trading
or other transactions of securities of the Company by insiders of the Company, including with respect to trading windows, as if Hill Path
were a director on the Board. Consistent with the Hill Path Designee’s obligation as a director of the Company to maintain the confidentiality
of any confidential non-public information concerning the Company (“Confidential Information”), the Hill Path Designee
agrees not to disclose or discuss any Confidential Information except in accordance with the Company Policies, including any confidentiality
agreement entered into by the Hill Path with the Company as a director thereof (the “Designee Confidentiality Agreement”);
provided, the Hill Path Designee may disclose Confidential Information to Hill Path and its Affiliates, officers, directors, employees
and outside advisors to in accordance with and to the extent permitted by such Designee Confidentiality Agreement. The Company represents
and warrants that all Company Policies currently in effect are publicly available on the Company’s website or described in its proxy
statement filed with the Securities and Exchange Commission (the “SEC”) on May 4, 2022 or have otherwise been
provided to Hill Path, and such Company Policies will not be amended prior to the appointment of the Hill Path Designee other than as
may be required to implement this Agreement or as required by law, regulation or the rules of any applicable national securities
exchange.

 

4.            Standstill.
From the date of this Agreement until the Expiration Date (such period, the “Restricted Period”), Hill Path and its
Affiliates will not, and will cause their respective principals, directors, general partners, officers, employees, and agents and representatives
acting on their behalf (collectively, the “Restricted Persons”) not to, directly or indirectly, absent prior express
written invitation or authorization by the Company or the Board:

 

(a)            engage
in any “solicitation” (as such term is defined under the Exchange Act) of proxies or consents with respect to the election
or removal of directors or any other matter or proposal or become a “participant” (as such term is defined in Instruction
3 to Item 4 of Schedule 14A promulgated under the Exchange Act) in any such solicitation of proxies or consents; provided, that such restriction
shall not restrict or prohibit Hill Path from initiating, engaging in, facilitating or publicly advocating for or responding to an Extraordinary
Transaction;

 

(b)            acquire,
offer or propose to acquire, or agree to acquire any securities of the Company, whether voting or non-voting, if, after giving effect
to such acquisition, Hill Path and its Affiliates (together with any individual or entity that would be deemed to be part of a “group”
(as such term is defined in Section 13(d)(3) of the Exchange Act) with Hill Path or any of its Affiliates would own, control
or otherwise have any beneficial or other ownership interest, including through the ownership of Synthetic Positions, in an amount in
excess of 20% of such class of securities of the Company outstanding at such time, based on the total number of such securities outstanding
as most recently disclosed by the Company on the cover of a publicly filed Form 10-K or Form 10-Q or otherwise disclosed or
communicated in writing by the Company to Hill Path;

 

    3

     

    

 

(c)            knowingly
encourage, advise or influence any other Person or knowingly assist any Person in so encouraging, advising or influencing any Person with
respect to the giving or withholding of any proxy, consent or other authority to vote or in conducting any type of referendum, binding
or non-binding, (other than such encouragement, advice or influence that is consistent with Company management’s recommendation
in connection with such matter); provided, that such restriction shall not restrict or prohibit Hill Path from initiating, engaging in,
facilitating or publicly advocating for or responding to an Extraordinary Transaction;

 

(d)            enter
into a voting trust, arrangement or agreement or subject any Voting Securities to any voting trust, arrangement or agreement, with respect
to Voting Securities now or hereafter owned by them and other than granting proxies in solicitations approved by the Board; provided,
that such restriction shall not restrict or prohibit Hill Path from initiating, engaging in, facilitating or publicly advocating for or
responding to an Extraordinary Transaction;

 

(e)            (i) seek,
alone or in concert with others, election or appointment to, or representation on, the Board or nominate or propose the nomination of,
or recommend the nomination of, any candidate to the Board, except as set forth herein, (ii) seek, alone or in concert with others,
the removal of any member of the Board or (iii) conduct a referendum of stockholders; provided, that such restriction (iii) shall
not restrict or prohibit Hill Path from initiating, engaging in, facilitating or publicly advocating for or responding to an Extraordinary
Transaction;

 

(f)            make
or be the proponent of any stockholder proposal (pursuant to Rule 14a-8 under the Exchange Act or otherwise); provided, that such
restriction shall not restrict or prohibit Hill Path from initiating, engaging in, facilitating or publicly advocating for or responding
to an Extraordinary Transaction;

 

(g)            except
as set forth herein, make any public proposal with respect to (i) any change in the number or term of directors or the filling of
any vacancies on the Board, (ii) any material change in the capitalization or dividend policy of the Company, (iii) any other
material change in the Company’s governance, management, business, strategy or corporate structure or (iv) any waiver, amendment
or modification to the Company’s Certificate of Incorporation or Bylaws; provided, that such restrictions (ii), (iii) and (iv) shall
not restrict or prohibit Hill Path from initiating, engaging in, facilitating or publicly advocating for or responding to an Extraordinary
Transaction;

 

(h)            institute,
solicit, assist or join any litigation, arbitration or other proceeding against or involving the Company or any of its current or former
directors or officers (including derivative actions) in order to effect or take any of the actions expressly prohibited by this Section 4;
provided, however, that for the avoidance of doubt the foregoing shall not prevent any Restricted Person from (i) bringing litigation
to enforce the provisions of this Agreement, (ii) making counterclaims with respect to any proceeding initiated by, or on behalf
of, the Company against a Restricted Person, (iii) bringing bona fide commercial disputes that do not relate to the subject matter
of this Agreement, or (iv) exercising statutory appraisal rights; provided, further, that the foregoing shall also not prevent the
Restricted Persons from responding to or complying with a validly issued legal process;

 

    4

     

    

 

(i)            enter
into any negotiations, agreements or understandings with any Third Party, or otherwise encouraging or facilitating any Third Party, in
each case to take any action that Hill Path is prohibited from taking pursuant to this Section 4; or

 

(j)            make
any request or submit any proposal, directly or indirectly, to amend or waive the terms of this Agreement, in each case which would reasonably
be expected to result in a public announcement of such request or proposal.

 

Notwithstanding anything to the contrary in this Agreement, during
the Restricted Period the Restricted Persons may not directly or indirectly seek or take any action with respect to the election or removal
of directors or any change to the composition, number or term of directors or the filling of any vacancies on the Board.

 

Notwithstanding anything to the contrary in this Agreement, nothing
in this Agreement shall prohibit or restrict (x) the Hill Path Designee from exercising his rights and fiduciary duties as a director
of the Company or restrict his discussions solely among other members of the Board and/or management, advisors, representatives or agents
of the Company and (y) the Board from forming an independent committee of the Board (which independent committee shall not include
the Hill Path Designee if such Hill Path Designee is determined to have a conflict of interest that is not approved or ratified by the
Audit Committee pursuant to the Company’s Related Party Transaction Policy and Code of Business Conduct and Ethics) if any of the
Restricted Persons (i) take any public position adverse to the interests of the Board or the Company as reasonably determined by
the Board or any committee thereof or (ii) subject to the Waiver (as defined below), would become an “interested person”
pursuant to DGCL 203 (as defined below).

 

5.            Delaware
General Corporation Law Section 203 Conditional Waiver.

 

(a)            The
Company hereby represents and warrants to Hill Path that, contingent upon the execution and delivery of this Agreement by the Hill Path
Parties, the Board has taken all action necessary to render inapplicable the restrictions on “business combinations” set forth
in Section 203 of the General Corporation Law of the State of Delaware (“DGCL 203”) solely in connection with
Hill Path, collectively with its Affiliates and “associates” (as defined in DGCL 203) (each of the foregoing, a “Hill
Path Entity”) becoming, whether in a single transaction or multiple transactions from time to time until the Expiration Date,
the beneficial owner of an aggregate less than 20% of the Voting Securities, including through the ownership of Synthetic Positions (the
 “Waiver”).

 

(b)            However,
in the event that the Hill Path Entities become the beneficial owner of an aggregate of 20% or more of the Voting Securities, including
through the ownership of Synthetic Positions, then from and after that date (the “Excess Date”), notwithstanding the
Waiver, DGCL 203 shall apply as described in Section 5(c) as if the Hill Path Entities beneficially owned 15% or more
of the voting power of the then issued and outstanding shares of Voting Securities commencing on the Excess Date and there were no Waiver
in effect from and after the Excess Date. Notwithstanding the foregoing, any transactions or other events, if any, that occurred during
the period when the Waiver was in effect shall not be deemed to have violated or triggered the applicability of DGCL 203 prior to the
Excess Date.

 

    5

     

    

 

(c)            Each
of the Hill Path Parties agrees, in each case on behalf of itself and its Affiliates, that if, at any time from the date of this Agreement
through the ten (10) year anniversary of the date of this Agreement, the Hill Path Entities become the beneficial owner of Voting
Securities such that the Hill Path Entities would in the aggregate beneficially own 20% or more of the Voting Securities, including through
the ownership of Synthetic Positions, under circumstances in which the restrictions on “business combinations” would, but
for the Waiver (and provided the definition of “beneficial ownership” in DGCL 203 shall be deemed replaced by the definition
of “beneficial ownership” in this Agreement), be applicable to the Company and Hill Path Entities (any event causing the Hill
Path Entities to own in excess of such amount, an “Additional Acquisition”), then, notwithstanding the Waiver, from
and after the Excess Date (i) the restrictions under DGCL 203 applicable to a “business combination” with an “interested
stockholder” shall apply as a matter of contract pursuant to this Agreement (except as modified herein) to the Hill Path Entities
as if such Waiver had not been granted and as if the Additional Acquisition had caused each of the Hill Path Entities to become an “interested
stockholder” for purposes of DGCL 203 (except that, for all purposes of this Agreement, references to “15%” in DGCL
203 shall be deemed to be replaced with “20%” and the definition of “beneficial ownership” in DGCL 203 shall be
deemed replaced by the definition of “beneficial ownership” in this Agreement and shall include through the ownership of Synthetic
Positions); and (ii) none of the Hill Path Entities shall engage in any “business combination” with the Company for a
period of 3 years following the Excess Date, unless any of the exceptions in subsections (a) or (b) of DGCL 203 apply.

 

6.            Press
Release; SEC Filings. No party shall make any statement inconsistent with the terms of this Agreement. Additionally, promptly
following the execution and delivery of this Agreement, the Company will file a Current Report on Form 8-K, which will report the
entry into this Agreement. Hill Path shall promptly, but in no case prior to the date of the filing or other public release by the Company
of the Press Release, prepare and file an amendment to the Schedule 13D with respect to the Company originally filed by Hill Path with
the SEC on December 20, 2019 (the “Schedule 13D”) reporting the entry into this Agreement and amending applicable
items to conform to its obligations hereunder. The amendment to the Schedule 13D and the Form 8-K shall each be consistent with the
terms of this Agreement, and shall be in form and substance reasonably acceptable to the Company and Hill Path.

 

7.            Non-Disparagement.
During the Restricted Period, the Company and Hill Path shall each refrain from making, and shall cause their respective Affiliates and
their respective principals, directors, members, general partners, officers and employees not to make or cause to be made any statement
or announcement including in any document or report filed with or furnished to the SEC or through the press, media, analysts or other
persons, that both relates to and constitutes an ad hominem attack on, or that both relates to and otherwise disparages, defames, slanders,
impugns or is reasonably likely to damage the reputation of, (a) in the case of statements or announcements by Hill Path: the Company
or any of its Affiliates, subsidiaries or advisors, or any of its or their respective current or former officers, directors or employees
(including, without limitation, any statements or announcements regarding the Company’s strategy, operations, performance, products
or services), and (b) in the case of statements or announcements by the Company: Hill Path’s advisors, employees or any person
who has served as an employee of Hill Path and its advisors. The foregoing shall not restrict the ability of any person to comply with
any subpoena or other legal process or respond to a request for information from any governmental authority with jurisdiction over the
party from whom information is sought or to enforce such person’s rights hereunder.

 

    6

     

    

 

8.            Hill
Path’s Representations and Warranties. Hill Path hereby represents and warrants that (a) this Agreement has been
duly authorized, executed and delivered by it and is a valid and binding obligation of Hill Path, enforceable against it in accordance
with its terms; (b) Hill Path has the right and power to control and cause its Affiliates to abide by their respective obligations
under this Agreement; and (c) as of the date of this Agreement, Hill Path owns approximately 10.3% of the Company’s outstanding
common stock and has economic exposure, including pursuant to any Synthetic Positions, to approximately 14.8% of the Company’s outstanding
common stock. Hill Path further represents and warrants that it is aware of the restrictions imposed by the U.S. securities laws on the
purchase or sale of securities by any person who has received material, non-public information from the issuer of such securities and
on the communication of such information to any other person when it is reasonably foreseeable that such other person is likely to purchase
or sell such securities in reliance upon such information.

 

9.            Company
Representations and Warranties. The Company represents and warrants that (a) this Agreement has been duly authorized,
executed and delivered by it and is a valid and binding obligation of the Company, enforceable against the Company in accordance with
its terms; (b) does not require the approval of the stockholders of the Company; and (c) does not and will not violate any law,
any order of any court or other agency of government, the Company’s Certificate of Incorporation or Bylaws, each as may be amended
from time to time, or any provision of any agreement or other instrument to which the Company or any of its properties or assets is bound,
or conflict with, result in a breach of, loss of a material benefit under, give any right of termination, amendment, acceleration or cancellation
of, or constitute (with due notice or lapse of time or both) a default under any such agreement or other instrument, or result in the
creation or imposition of, or give rise to, any material lien, charge, restriction, claim, encumbrance or adverse penalty of any nature
whatsoever pursuant to any such indenture, agreement or other instrument.

 

10.            Specific
Performance. The Company and Hill Path acknowledge and agree that money damages would not be a sufficient remedy for any breach
(or threatened breach) of this Agreement by it and that, in the event of any breach or threatened breach hereof, (a) the non-breaching
party will be entitled to injunctive and other equitable relief, without proof of actual damages; (b) the breaching party will not
plead in defense thereto that there would be an adequate remedy at law; and (c) the breaching party agrees to waive any applicable
right or requirement that a bond be posted by the non-breaching party. Such remedies will not be the exclusive remedies for a breach of
this Agreement, but will be in addition to all other remedies available at law or in equity.

 

    7

     

    

 

11.            Entire
Agreement; Successors and Assigns; Amendment and Waiver. This Agreement (including its exhibits) constitutes the only agreement
between Hill Path and the Company with respect to the subject matter hereof and supersedes all prior agreements, understandings, negotiations
and discussions, whether oral or written. This Agreement shall be binding upon and inure to the benefit of the parties and their respective
successors and permitted assigns. No party may assign or otherwise transfer either this Agreement or any of its rights, interests, or
obligations hereunder without the prior written approval of the other party. Any purported transfer requiring consent without such consent
shall be void. No amendment, modification, supplement or waiver of any provision of this Agreement shall be effective unless it is in
writing and signed by the party affected thereby, and then only in the specific instance and for the specific purpose stated therein.
Any waiver by any party of a breach of any provision of this Agreement shall not operate as or be construed to be a waiver of any other
breach of such provision or of any breach of any other provision of this Agreement. The failure of a party to insist upon strict adherence
to any term of this Agreement on one or more occasions shall not be considered a waiver or deprive that party of the right thereafter
to insist upon strict adherence to that term or any other term of this Agreement.

 

12.            Severability.
If any provision of this Agreement is held invalid or unenforceable by any court of competent jurisdiction, the other provisions of this
Agreement shall remain in full force and effect. Any provision of this Agreement held invalid or unenforceable only in part or degree
shall remain in full force and effect to the extent not held invalid or unenforceable. The parties further agree to replace such invalid
or unenforceable provision of this Agreement with a valid and enforceable provision that will achieve, to the extent possible, the purposes
of such invalid or unenforceable provision.

 

13.            Governing
Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware. Each of Hill Path
and the Company (a) irrevocably and unconditionally consents to the personal jurisdiction and venue of the Delaware Court of Chancery
and any state appellate court therefrom within the State of Delaware (or, if the Delaware Court of Chancery declines to accept jurisdiction
over a particular matter, any federal court within the State of Delaware); (b) agrees that it shall not attempt to deny or defeat
such personal jurisdiction by motion or other request for leave from any such court; (c) agrees that it shall not bring any action
relating to this Agreement or otherwise in any court other than such courts; and (d) waives any claim of improper venue or any claim
that those courts are an inconvenient forum. The parties agree that mailing of process or other papers in connection with any such action
or proceeding in the manner provided in Section 15 or in such other manner as may be permitted by applicable law, shall be
valid and sufficient service thereof. Each of the parties, after consulting or having had the opportunity to consult with counsel, knowingly,
voluntarily and intentionally waives any right that such party may have to a trial by jury in any litigation based upon or arising out
of this Agreement or any related instrument or agreement, or any of the transactions contemplated thereby, or any course of conduct, dealing,
statements (whether oral or written), or actions of any of them. No party shall seek to consolidate, by counterclaim or otherwise, any
action in which a jury trial has been waived with any other action in which a jury trial cannot be or has not been waived.

 

14.            Parties
in Interest. This Agreement is solely for the benefit of the parties and is not enforceable by any other Person.

 

    8

     

    

 

15.            Notices.
All notices, consents, requests, instructions, approvals and other communications provided for herein, and all legal process in regard
hereto, will be in writing and will be deemed validly given, made or served when delivered in person, by electronic mail, by overnight
courier or two business days after being sent by registered or certified mail (postage prepaid, return receipt requested) as follows:

 

If to the Company to:

 

Dave & Buster’s Entertainment, Inc.

1221 S. Beltline Road, Suite 500

Coppell, TX 75019

Attn: Rob Edmund

Email: rob.edmund@daveandbusters.com

 

with a copy (which shall not constitute notice) to:

 

Paul,
Weiss, Rifkind, Wharton & Garrison LLP

1285 Avenue of the Americas

New York, NY 10019

Attn: Robert B. Schumer; Cullen Sinclair

Email: rschumer@paulweiss.com; csinclair@paulweiss.com

 

If to Hill Path or the Hill Path Designee

 

Hill Path Capital LP

150 East 58th Street, 32nd Floor

New York, New York 10155

Attn: James Chambers

Email: chambers@hillpathcap.com

 

with a copy (which shall not constitute notice) to:

 

Olshan Frome Wolosky LLP

1325 Avenue of the Americas

New York, NY 10019

Attn: Steve Wolosky

Email: swolosky@olshanlaw.com

 

At any time, any party may, by notice given in accordance with this
Section 15 to the other party, provide updated information for notices hereunder.

 

16.            Legal
Fees. Each party hereto shall be responsible for its own fees and expenses (including legal expenses) incurred in connection
with the negotiation and execution of this Agreement and the actions contemplated hereby.

 

17.            Interpretation.
Each of the parties acknowledges that it has been represented by counsel of its choice throughout all negotiations that have preceded
the execution of this Agreement, and that it has executed this Agreement with the advice of such counsel. Each party and its counsel cooperated
and participated in the drafting and preparation of this Agreement, and any and all drafts relating thereto exchanged among the parties
shall be deemed the work product of all of the parties and may not be construed against any party by reason of its drafting or preparation.
Accordingly, any rule of law or any legal decision that would require interpretation of any ambiguities in this Agreement against
any party that drafted or prepared it is of no application and is hereby expressly waived by each of the parties, and any controversy
over interpretations of this Agreement shall be decided without regard to events of drafting or preparation.

 

    9

     

    

 

18.            Counterparts.
This Agreement may be executed by the parties in separate counterparts (including by fax, jpeg, .gif, .bmp and .pdf), each of which when
so executed shall be an original, but all such counterparts shall together constitute one and the same instrument.

 

[Signature page follows]

 

    10

     

    

 

Accepted and agreed as of the date first written above:

 

 

Dave & Buster’s Entertainment, Inc.

 

	By:	/s/ Robert W. Edmund	 

Name: Robert W. Edmund

Title: General Counsel, Secretary and Senior Vice President of Human Resources

 

[Signature
Page to Amended and Restated Cooperation Agreement]

 

    

     

    

 

Accepted and agreed (including on behalf of the Affiliates of the below)
as of the date first written above:

 

 

James Chambers

 

	/s/ James Chambers	 

 

 

Hill Path Capital LP

 

By: Hill Path Holdings LLC, its General Partner

 

	/s/ Scott Ross	 

Name: Scott Ross

Title: Managing Partner

 

[Signature
Page to Amended and Restated Cooperation Agreement]Exhibit 10.1

 

NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION
OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE
OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

SERIES
A

 

COMMON
STOCK PURCHASE WARRANT

 

VIVOS,
INC.

 

	Warrant Shares:	Issue Date: July 7, 2022

 

THIS
SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ___________ its assigns
(the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter
set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business
on December 31, 2022 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Vivos, Inc.,
a Delaware corporation (the “Company”), up to 5,000,000 shares (as subject to adjustment hereunder, the “Warrant
Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise
Price, as defined in Section 2(b).

 

Section
1. Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain
Warrant Purchase Agreement (the “Purchase Agreement”), dated June 30, 2022.

 

Section
2. Exercise.

 

a) Exercise
of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times
on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company (or such other office or
agency of the Company as it may designate by notice in writing to the registered Holder at the address of the Holder appearing on
the books of the Company) of a duly executed facsimile copy (or e-mail attachment) of the Notice of Exercise
in the form annexed hereto and within three (3) Trading Days of the date said Notice of Exercise is delivered to the Company, the
Company shall have received payment of the aggregate Exercise Price of the shares thereby purchased by wire transfer or
cashier’s check drawn on a United States bank or, if available, pursuant to the cashless exercise procedure specified in
Section 2(c) below. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of
guarantee or notarization) of any Notice of Exercise form be required. Notwithstanding anything herein to the contrary, the Holder
shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares
available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the
Company for cancellation within three (3) Trading Days of the date the final Notice of Exercise is delivered to the Company. Partial
exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have
the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of
Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the
date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of
such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of
this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for
purchase hereunder at any given time may be less than the amount stated on the face hereof.

 

    	1

     

    

 

b) Exercise
Price. The exercise price per share of the Common Stock under this Warrant shall be one ($.01) cent, subject to adjustment
hereunder (the “Exercise Price”).

 

c) Cashless
Exercise. If at any time after the six month anniversary of the date of the Purchase Agreement, there is no effective
Registration Statement registering, or no current prospectus available for, the resale of the Warrant Shares by the Holder, then
this Warrant may also be exercised, in whole or in part, at such time by means of a “cashless exercise” in which the
Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A),
where:

 

	 	(A)
    = 	the
    VWAP on the Trading Day immediately preceding the date on which Holder elects to exercise this Warrant by means of a “cashless
    exercise,” as set forth in the applicable Notice of Exercise;
	 	 	 
	 	(B)
    = 	the
    Exercise Price of this Warrant, as adjusted hereunder; and
	 	 	 
	 	(X)
    = 	the
    number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such
    exercise were by means of a cash exercise rather than a cashless exercise.

 

If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act the holding period of the Warrants being exercised may be tacked on to the holding period of the Warrant Shares. The Company
agrees not to take any position contrary to this Section 2(c).

 

    	2

     

    

 

“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCBB, OTCQB or OTCQX is not a Trading Market, the volume weighted
average price of the Common Stock for such date (or the nearest preceding date) on OTCBB, OTCQB or OTCQX as applicable, (c) if the Common
Stock is not then listed or quoted for trading on OTCBB, OTCQB or OTCQX and if prices for the Common Stock are then reported in the “Pink
Sheets” published by OTC Markets, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the
most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common
Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then
outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

 

Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section 2(c).

 

 d) Mechanics of Exercise.

 

i. Delivery
of Warrant Shares Upon Exercise. Warrant Shares purchased hereunder shall be transmitted by the Transfer Agent to the Holder by
crediting the account of the Holder’s or its designee’s balance account with The Depository Trust Company through its
Deposit or Withdrawal at Custodian system (“DWAC”) if the Company is then a participant in such system and either
(A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by
the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to
Rule 144, and otherwise by physical delivery of a certificate, registered in the Company’s share register in the name of the
Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address
specified by the Holder in the Notice of Exercise by the date that is three (3) Trading Days after the delivery to the Company of
the Notice of Exercise (such date, the “Warrant Share Delivery Date”). Upon delivery of the Notice of Exercise
the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to
which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares; provided payment of the aggregate
Exercise Price (other than in the case of a Cashless Exercise) is received within three Trading
Days of delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject
to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and
not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of
the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the fifth Trading Day after such
liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are
delivered or Holder rescinds such exercise.

 

    	3

     

    

 

ii. Delivery
of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder
and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall
in all other respects be identical with this Warrant.

 

iii. Rescission
Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section
2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.

 

iv. Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to the Holder,
if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of
Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is
required by its broker to purchase (in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise
purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder
anticipated receiving upon such exercise (a “Buy-In”), then the Company shall (A) pay in cash to the Holder the
amount, if any, by which (x) the Holder’s total purchase price (including brokerage commissions, if any) for the shares of
Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was
required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise
to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and
equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded)
or deliver to the Holder the number of shares of Common Stock that would have been issued had
the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock
having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an
aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the
Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts
payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein
shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without
limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver
shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.

 

    	4

     

    

 

v. No
Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of
this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction
multiplied by the Exercise Price or round up to the next whole share.

 

vi. Charges,
Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other
incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company,
and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however,
that in the event Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a
condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay
all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or
another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant
Shares.

 

vii. Closing
of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this
Warrant, pursuant to the terms hereof.

 

    	5

     

    

 

e) Holder’s
Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to
exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance
after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and any
other Persons acting as a group together with the Holder or any of the Holder’s Affiliates, such other Persons,
“Attribution Parties”)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined
below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder, its
Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with
respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable
upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates
or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the
Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise
analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.
Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in
accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the
Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange
Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the
limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other
securities owned by the Holder together with any Affiliates or Attribution Parties) and of which portion of this Warrant is
exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the
Holder’s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together
with any Affiliates or Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the
Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination.
In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of
the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number
of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the
Company’s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public
announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of
shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within two Trading Days confirm
orally or in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding
shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including
this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of
Common Stock was reported. The “Beneficial Ownership Limitation” shall be 4.99% of the number of shares of the
Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this
Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this
Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common
Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by
the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will
not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be
construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this
paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein
contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations
contained in this paragraph shall apply to a successor holder of this Warrant.

 

    	6

     

    

 

Section
3. Certain Adjustments.

 

a) Stock
Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in
shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon
exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines
(including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues by
reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price
shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares,
if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock
outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately
adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section
3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such
dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination
or re-classification.

 

b) Subsequent
Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or
sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will be entitled to
acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if
the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any
limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on
which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of
which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights
(provided, however, to the extent that the Holder’s right to participate in any such Purchase Right would result in the Holder
exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such
extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase
Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the
Holder exceeding the Beneficial Ownership Limitation).

 

    	7

     

    

 

c) Pro
Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other
distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or
otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a
dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a
“Distribution”), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be
entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had
held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on
exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is
taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are
to be determined for the participation in such Distribution (provided, however, to the extent that the Holder’s
right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the
Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of
Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the
benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial
Ownership Limitation).

 

d) Fundamental
Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or
indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of
its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer
(whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or
exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding
Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification,
reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is
effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one
or more related transactions consummates a stock or share purchase agreement or other business combination (including, without
limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person or group of Persons whereby
such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common
Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or
party to, such stock or share purchase agreement or other business combination) (each a “Fundamental
Transaction”), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each
Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction,
at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares
of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional
consideration (the “Alternate Consideration”) receivable as a result of such Fundamental Transaction by a holder
of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction
(without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the
determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of
Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall
apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different
components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to
be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it
receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in a
Fundamental Transaction in which the Company is not the survivor (the “Successor Entity”) to assume in writing
all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of
this Section 3(e) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and shall, at the
option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written
instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of
capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable
upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental
Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into
account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of
capital stock, such number of shares of capital stock and such exercise price being for the
purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and
which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the
Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the
provisions of this Warrant and the other Transaction Documents referring to the “Company” shall refer instead to the
Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company
under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named as the
Company herein.

 

    	8

     

    

 

e) Calculations.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For
purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the
sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

 f) Notice to Holder.

 

i. Adjustment
to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall notify
the Holder a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant
Shares and setting forth a brief statement of the facts requiring such adjustment.

 

Section
4. Transfer of Warrant.

 

a) Transferability.
Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof and to the provisions
of Section 4.1 of the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation, any registration
rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its
designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the
Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such
surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the
assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall
issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be
cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to
the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the
Company within three (3) Trading Days of the date the Holder delivers an assignment form to the Company assigning this Warrant full.
The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares
without having a new Warrant issued.

 

New
Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in
accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the original Issue Date and shall be identical
with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

 

    	9

     

    

 

b) Warrant
Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the
“Warrant Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat
the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the
Holder, and for all other purposes, absent actual notice to the contrary.

 

c) Representation
by the Holder. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any
exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for
distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state
securities law, except pursuant to sales registered or exempted under the Securities Act.

 

Section
5. Miscellaneous.

 

a) No
Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends or other rights
as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in
Section 3.

 

b) Loss,
Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the
Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if
mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in
lieu of such Warrant or stock certificate.

 

c) Saturdays,
Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or
granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding
Business Day.

 

    	10

     

    

 

 d) Authorized Shares.

 

The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a
sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with
the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all
such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise
of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly
issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof
(other than taxes in respect of any transfer occurring contemporaneously with such issue).

 

e) Jurisdiction.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in
accordance with the provisions of the Purchase Agreement.

 

f) Restrictions.
The Holder acknowledges that the Warrant Shares acquired upon of this Warrant, if not registered and the Holder does not utilize the
cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.

 

g) Nonwaiver
and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate
as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies, notwithstanding the fact that all
rights hereunder terminate on the Termination Date. If the Company willfully and knowingly fails to comply with any provision of
this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be
sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those of
appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its
rights, powers or remedies hereunder.

 

h) Notices.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered
in accordance with the notice provisions of the Purchase Agreement.

 

i) Limitation
of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase
Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder
for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or
by creditors of the Company.

 

    	11

     

    

 

j) Remedies.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to
specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation
for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the
defense in any action for specific performance that a remedy at law would be adequate.

 

k) Successors
and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to
the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of
Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall
be enforceable by the Holder or holder of Warrant Shares.

 

l) Amendment.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the
Holder.

 

m) Severability.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision
shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the
remaining provisions of this Warrant.

 

n)
Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed
a part of this Warrant.

 

********************

 

(Signature
Page Follows)

 

    	12

     

    

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.

 

	 	VIVOS, INC.
	 	 
	 	By:	 
	 	Name:	Michael K. Korenko
	 	Title:	CEO

 

    	13

     

    

 

NOTICE
OF EXERCISE

TO:
VIVOS, INC.

 

(1)
The undersigned hereby elects to purchase_______________ Warrant Shares of the Company pursuant to the terms of the attached Warrant
(only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer
taxes, if any.

 

 (2) Payment shall take the form of

 

(check applicable box): [   ] in

 

lawful money of the United States; or

 

[   ] [if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).

 

(3)
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

_______________________________________

 

The
Warrant Shares shall be delivered to the following DWAC Account Number:

 

_______________________________________

 

_______________________________________

 

_______________________________________

 

(4) Accredited
Investor. The undersigned is an “accredited investor” as defined in Regulation D promulgated under the Securities
Act of 1933, as amended.

 

[SIGNATURE
OF HOLDER]

 

Name
of Investing Entity: _________ Signature of Authorized Signatory of Investing Entity: _________ Name of Authorized Signatory:
_________ Title of Authorized Signatory: _________ Date:  _________

 

    	14

     

    

 

EXHIBIT
B

 

ASSIGNMENT
FORM

 

(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)

 

FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to Name:

 

	 	 
	 	(Please
    Print)
	 	 
	 	 
	 	 
	Address:	 
	(Please
    Print)	 
	Phone
    Number:	 
	Email
    Address:	 

 

	Dated:
    	 	 
	 	 	 
	Holder’s
    Signature:	 	 
	 	 	 
	Holder’s
    Address:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}]]